Join us at Health Research Day — June 6th at Canton Waterfront Park, Baltimore!   Learn More →
← Back to all trials
Completed NCT01520792

Paracetamol and Pharmacogenetic

Conditions: Healthy

Sex: Male
Ages: 18 Years – 30 Years
Healthy volunteers: Yes
Phase: PHASE1
Enrollment: 100
Sponsor: University Hospital, Clermont-Ferrand

Location: CHU Clermont-Ferrand Clermont-Ferrand

Summary

Recent works has emphasized that the mechanism of action of paracetamol analgesic depend on its metabolism in the body, since a breakdown product of paracetamol, the AM404 is now considered the analgesic metabolite of paracetamol suggesting as paracetamol may be a pro-drug. Indeed, it has been shown that paracetamol may have a deleterious effect, especially in vulnerable populations (hepatic insufficiency, elderly). First results showed a very significant decrease in sulfatation and gluthatione and increased phase 1 metabolism of acetaminophen, which involves enzymes such as cytochrome P450. Multifactorial causes, combining nutrition (depletion of sulfur amino acids), increased detoxification of toxic metabolites of paracetamol, stress or trauma are discussed to explain the results. Clinical studies showed a great variability of pain assessment by patients and variability in the metabolic response of paracetamol. Genetic factors probably play a role remains largely unknown. The review of the literature on genetic polymorphism shows the involvement of a number of enzymes that are well known, predominantly on the metabolism of acetaminophen liver, but without connection with its analgesic effect. This is a critical missing link in the understanding of the analgesic effect of paracetamol.

Eligibility Criteria

Inclusion Criteria: * Healthy volunteers * Males * Aged between 18 and 30 years Exclusion Criteria: * Subject without cons-indications of paracetamol

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT01520792). StuddyBuddy aggregates publicly available trial information.